R Donald Harvey

R Donald Harvey

UNVERIFIED PROFILE

Are you R Donald Harvey?   Register this Author

Register author
R Donald Harvey

R Donald Harvey

Publications by authors named "R Donald Harvey"

Are you R Donald Harvey?   Register this Author

80Publications

1697Reads

44Profile Views

A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".

JAMA Oncol 2019 Oct 17. Epub 2019 Oct 17.

The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.4129DOI Listing
October 2019

Reply to Tumor-associated macrophages: "Good cop-bad cop".

Cancer 2019 Jun 12;125(11):1942-1943. Epub 2019 Feb 12.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32015DOI Listing
June 2019

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

J Pharmacol Exp Ther 2019 May 14;369(2):291-299. Epub 2019 Mar 14.

Medical Oncology Department, Ramón y Cajal Hospital, Madrid, Spain (E.G.); Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia (R.D.H., S.S.R.); Medical Oncology, Faculté de Médecine Lyon-Sud, Université Claude Bernard Lyon-1, Institute de Cancérologie des Hospices Civils de Lyon, Lyon, France (B.Y.); Medical Oncology Department, La Paz University Hospital, Autonoma University of Madrid (affiliated with CIBERONC-Instituto de Salud Carlos III), Madrid, Spain (J.F.B.); IQVIA, Kansas City, Missouri (H.G.); Institute for Drug Development, Mays Cancer Center at University of Texas, Health San Antonio, San Antonio, Texas (J.S.); Global Medicines Development, AstraZeneca, Cambridge, United Kingdom (H.M., K.S.); and Quantitative Clinical Pharmacology, Early Clinical Development IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom (M.J., K.V.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.118.255919DOI Listing
May 2019

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.

J Oncol Pharm Pract 2019 Apr 31;25(3):613-622. Epub 2018 Jul 31.

2 Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155218788706DOI Listing
April 2019

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Clin Pharmacokinet 2019 Apr;58(4):431-449

Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40262-018-0702-1
Publisher Site
http://dx.doi.org/10.1007/s40262-018-0702-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397141PMC
April 2019

Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and Echoes.

Authors:
R Donald Harvey

J Oncol Pract 2019 Feb;15(2):91-92

1 Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00721DOI Listing
February 2019

Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.

Ther Adv Med Oncol 2019 6;11:1758835918818335. Epub 2019 Jan 6.

Winship Cancer Institute, School of Medicine, Emory University, 1365B Clifton Road NE B4300, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918818335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327341PMC
January 2019

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Br J Clin Pharmacol 2018 12 10;84(12):2877-2888. Epub 2018 Oct 10.

Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.13753
Publisher Site
http://dx.doi.org/10.1111/bcp.13753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256010PMC
December 2018

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Cancer 2018 11 10;124(22):4358-4365. Epub 2018 Oct 10.

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31746
Publisher Site
http://dx.doi.org/10.1002/cncr.31746DOI Listing
November 2018

Rationale, Opportunities, and Reality of Biosimilar Medications.

N Engl J Med 2018 08;379(7):694-695

Emory University, Atlanta, GA

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1808348
Publisher Site
http://dx.doi.org/10.1056/NEJMc1808348DOI Listing
August 2018

Reply to S.D. Lucio.

J Clin Oncol 2018 07 30;36(20):2127. Epub 2018 May 30.

Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle WA; Robin Zon, Michiana Hematology Oncology, Mishawaka, IN; R. Donald Harvey, Emory University, Atlanta GA; and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.1780DOI Listing
July 2018

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

J Clin Oncol 2018 05 28;36(14):1389-1395. Epub 2018 Mar 28.

Russell Z. Szmulewitz, Abiola Ibraheem, Elia Martinez, Mark F. Kozloff, Chadi Nabhan, Theodore Karrison, Walter M. Stadler, and Mark J. Ratain, The University of Chicago, Chicago; Mark F. Kozloff, Ingalls Hospital, Harvey; Paul Fishkin, Illinois Cancer Care, Peoria, IL; Cody J. Peer and William D. Figg, National Cancer Institute, Rockville, MD; Bradley Carthon and R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA; and Wei Peng Yong and Edmund Chiong, National University Cancer Institute, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.4381
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.4381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941614PMC
May 2018

Rationale, Opportunities, and Reality of Biosimilar Medications.

N Engl J Med 2018 May;378(21):2036-2044

From the Fred Hutchinson Cancer Research Center, Seattle (G.H.L.); Michiana Hematology Oncology, Mishawaka, IN (R.Z.); Emory University, Atlanta (R.D.H.); and the American Society of Clinical Oncology, Alexandria, VA (R.L.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMhle1800125DOI Listing
May 2018

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

J Clin Oncol 2018 04 14;36(12):1260-1265. Epub 2018 Feb 14.

Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA; Edward Balaban, University of Pennsylvania Medical College, Philadelphia, PA; Michael Diaz, Florida Cancer Specialists and Research Institute, St Petersburg, FL; Andrea Ferris, Lungevity Foundation, Bethesda, MD; Anne Tsao, The University of Texas MD Anderson Cancer Center, Houston, TX; Emile Voest, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Robin Zon, Michiana Hematology Oncology, Mishawaka, IN; Michael Francisco, Sybil Green, Shimere Sherwood, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; and R. Donald Harvey, Emory University School of Medicine, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4893DOI Listing
April 2018

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Clin Pharmacokinet 2017 11;56(11):1355-1368

Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street , Cambridge, MA, 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-017-0526-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648746PMC
November 2017

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

J Clin Oncol 2017 Nov 2;35(33):3753-3759. Epub 2017 Oct 2.

Stuart M. Lichtman, Memorial Sloan Kettering Cancer Center, Commack, NY; R. Donald Harvey, Emory University School of Medicine, Atlanta, GA; Marie-Anne Damiette Smit and Atiqur Rahman, US Food and Drug Administration, Silver Spring, MD; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; Nancy Roach, Fight Colorectal Cancer, Springfield, MO; Caroline Schenkel and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Patricia Cortazar, Genentech, South San Francisco; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo, CA; and Dana Walker, Bristol-Myers Squibb, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.4102DOI Listing
November 2017

Science of Biosimilars.

Authors:
R Donald Harvey

J Oncol Pract 2017 09;13(9_suppl):17s-23s

Winship Cancer Institute of Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.026062DOI Listing
September 2017

Preventing and Managing Toxicities of High-Dose Methotrexate.

Oncologist 2016 12 5;21(12):1471-1482. Epub 2016 Aug 5.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153332PMC
December 2016

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

Cancer 2016 Nov 15;122(22):3424-3427. Epub 2016 Aug 15.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30273DOI Listing
November 2016

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.

Expert Rev Clin Pharmacol 2016 26;9(1):35-48. Epub 2015 Oct 26.

d CIMA, IDISNA , Clínica Universidad de Navarra , Pamplona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2016.1096773DOI Listing
June 2016

Calcium and Cancer: Of Evil Humors and Innocent Bystanders.

Authors:
R Donald Harvey

J Oncol Pract 2016 05;12(5):433-4

Emory University, Atlanta, GA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.012385DOI Listing
May 2016

Navigating the Landscape of Molecular Testing and Targeted Treatment of Non-Small Cell Lung Cancer.

J Adv Pract Oncol 2016 Apr 1;7(3):299-301. Epub 2016 Apr 1.

Stanford University School of Medicine, Palo Alto, California, and Emory University School Medicine, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679045PMC
April 2016

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.

Cancer 2015 Mar 6;121(6):853-62. Epub 2014 Nov 6.

Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29136DOI Listing
March 2015

Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.

Clin Colorectal Cancer 2014 Dec 21;13(4):219-25. Epub 2014 Sep 21.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2014.09.007DOI Listing
December 2014

Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.

Clin Pharmacol Ther 2014 Oct 2;96(4):449-57. Epub 2014 Jul 2.

Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1038/clpt.2014.143
Publisher Site
http://dx.doi.org/10.1038/clpt.2014.143DOI Listing
October 2014

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.

Authors:
R Donald Harvey

Clin Pharmacol 2014 8;6:87-96. Epub 2014 May 8.

Phase 1 Clinical Trials Section, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CPAA.S62512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020895PMC
June 2014

Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.

Clin Lymphoma Myeloma Leuk 2014 Apr 15;14(2):e59-63. Epub 2013 Nov 15.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650130047
Publisher Site
http://dx.doi.org/10.1016/j.clml.2013.11.007DOI Listing
April 2014

Taxanes: vesicants, irritants, or just irritating?

Ther Adv Med Oncol 2014 Jan;6(1):16-20

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834013510546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866993PMC
January 2014

Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.

Biol Blood Marrow Transplant 2013 Sep 10;19(9):1393-5. Epub 2013 Jun 10.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.06.003DOI Listing
September 2013

Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.

Clin Lymphoma Myeloma Leuk 2013 Apr 17;13(2):159-61. Epub 2012 Oct 17.

Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S215226501200165
Publisher Site
http://dx.doi.org/10.1016/j.clml.2012.09.005DOI Listing
April 2013

Tools to optimize the functionality of a leukemia clinical trial team.

Leuk Lymphoma 2013 Jan 13;54(1):110-6. Epub 2012 Aug 13.

Clinical Trials Office of Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.708929DOI Listing
January 2013

Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.

Cancer 2012 Sep 31;118(18):4571-8. Epub 2012 Jan 31.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27397DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342458PMC
September 2012

Iron overload in myelodysplastic syndromes. Introduction.

Am J Health Syst Pharm 2010 Apr;67(7 Suppl 2):S2

Department of Hematology/Medical Oncology, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/ajhp/article/67/7_Supplement_2/S2/5
Publisher Site
http://dx.doi.org/10.2146/ajhp100043DOI Listing
April 2010

Myelodysplastic syndromes and the role of iron overload.

Authors:
R Donald Harvey

Am J Health Syst Pharm 2010 Apr;67(7 Suppl 2):S3-9

Department of Hematology/Medical Oncology, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp090645DOI Listing
April 2010

Through the looking glass: the evolution of erythropoiesis-stimulating agent use.

Oncology (Williston Park) 2010 Mar;24(3):269, 274

Ambulatory Treatment Center, Emory Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia USA.

View Article

Download full-text PDF

Source
March 2010

Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology.

Am J Health Syst Pharm 2010 Jan;67(1 Suppl 1):S3-9, quiz S15-6

Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington 40536, USA.

View Article

Download full-text PDF

Source
http://www.ajhp.org/cgi/doi/10.2146/ajhp090456
Publisher Site
http://dx.doi.org/10.2146/ajhp090456DOI Listing
January 2010

PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.

Future Oncol 2007 Dec;3(6):639-47

Emory University School of Medicine, Winship Cancer Institute, 1365 C Clifton Road, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/14796694.3.6.639
Publisher Site
http://dx.doi.org/10.2217/14796694.3.6.639DOI Listing
December 2007

Novel therapeutic agents in the management of hemorrhage and thrombosis.

Cardiovasc Hematol Agents Med Chem 2006 Oct;4(4):319-34

Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
October 2006

Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction.

Authors:
R Donald Harvey

Pharmacotherapy 2005 Nov;25(11 Pt 2):71S-72S

Grady Health System, Georgia Cancer Center for Excellence, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.2005.25.11part2.71SDOI Listing
November 2005

The patient: Emerging clinical applications of intravenous immunoglobulin.

Authors:
R Donald Harvey

Pharmacotherapy 2005 Nov;25(11 Pt 2):85S-93S

Grady Health System, Georgia Cancer Center for Excellence, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1592/phco.2005.25.11part2.85S
Publisher Site
http://dx.doi.org/10.1592/phco.2005.25.11part2.85SDOI Listing
November 2005